Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 20.75 14,929 08:00:29
Bid Price Offer Price High Price Low Price Open Price
20.00 21.50 20.75 20.75 20.75
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 84.33 3.66 0.45 46.1 134
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:00 O 140 21.50 GBX

Allergy Therapeutics (AGY) Latest News (1)

More Allergy Therapeutics News
Allergy Therapeutics Investors    Allergy Therapeutics Takeover Rumours

Allergy Therapeutics (AGY) Discussions and Chat

Allergy Therapeutics (AGY) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-07-01 15:35:0121.5014030.10O
2022-07-01 15:35:0021.508718.71O
2022-07-01 15:35:0021.5010021.50O
2022-07-01 15:35:0021.50469.89O
2022-07-01 15:35:0020.00408.00O
View all Allergy Therapeutics trades in real-time

Allergy Therapeutics (AGY) Top Chat Posts

DateSubject
01/7/2022
09:20
Allergy Therapeutics Daily Update: Allergy Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 20.75p.
Allergy Therapeutics Plc has a 4 week average price of 20.75p and a 12 week average price of 20.75p.
The 1 year high share price is 40p while the 1 year low share price is currently 20.25p.
There are currently 643,597,146 shares in issue and the average daily traded volume is 18,398 shares. The market capitalisation of Allergy Therapeutics Plc is £133,546,407.80.
30/6/2022
15:22
raleigh43: Well I am holding and buying as I think that the coming good news will be a massive boost for the share price.
24/5/2022
08:22
wizzkid211: Allergy Therapeutics PLC 23 May 2022 Allergy Therapeutics plc (" A l l e r gy T he r a peu t i cs", the "Group" or " C o m p a n y " ) Allergy Therapeutics to Present at the H.C. Wainwright Global Investment Conference 23 May 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that company management will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually. The virtual presentation will be available to registered attendees of the conference for on-demand viewing beginning May 24, 2022 at 7:00 a.m. ET/12:00 p.m. BST. A replay of the presentation will be made available under the 'Investors' section on Allergy Therapeutics' website at www.allergytherapeutics.com/investors/results-reports-and-presentations/ . - ENDS - hTTps://www.advfn.com/stock-market/london/AGY/stock-news/88177322/allergy-therapeutics-plc-allergy-therapeutics-at-h?xref=newsalert
25/4/2022
07:18
jimmyloser: ALIVE AND KICKING.......... Allergy Therapeutics shares positive data at the 2022 WAO-BSACI Conference 25 April 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, will share positive new data from across its research portfolio at the joint WAO (World Allergy Organisation) & BSACI ( British Society for Allergy & Clinical Immunology) 2022 UK Conference in Edinburgh, Scotland, from 25 to 27 April 2022. Potential novel grass pollen immunotherapy The first of the Group's posters presents findings from the exploratory field study (G309) conducted to further optimise the trial design of the upcoming pivotal Phase III clinical trial (G306) investigating the Group's wholly owned short-course grass pollen immunotherapy candidate, Grass MATA MPL. Data from the study, conducted in the US and EU, show that the immunotherapy demonstrated clinically relevant and statistically significant reductions in the daily symptoms and the use of relief medications after 6 subcutaneous allergen-specific immunotherapy (SCIT) injections in two different treatment regimens. The results highlight the potential of this novel, short-course immunotherapy targeting grass pollen allergies and support the route to registration in both Europe and the US. Real-World-Evidence data of MCT(R)-associated allergoid SCIT platform Another poster reports on the Group's TARGET study. Real-World-Evidence data are becoming increasingly important for academia but also regulators. Real-World-Evidence allow insights into the therapeutic effectiveness of a drug but also disease modification and or long-term effectiveness of allergen immunotherapy (AIT). The aim of the "Tyrosine Allergoid Real World Evidence in Germany Effectiveness in AIT" (TARGET) study was to demonstrate the long-term benefit of MCT(R) -associated allergoid SCIT in routine clinical practice. The progression of allergic rhinitis (AR) and asthma was measured in patients receiving one of three allergoid SCIT in comparison to matched control groups without AIT using prescription data of more than 181,000 German patients within the statutory health insurance system based on the IMS(R) LRx database (IQVIA, Germany). The TARGET study demonstrated long-term benefits of allergoid SCIT including MCT(R)-associated allergoids on AR and asthma up to 9.5 years (Ø 6.3 years) of follow up in routine clinical practice. The hypo-allergic potential of VLP Peanut against peanut exposure The latest pre-clinical mechanistic data on Allergy Therapeutics' peanut vaccine candidate, VLP Peanut, will also be showcased in a poster which illustrates how a vaccine incorporating the major peanut allergen (recombinant Ara h 2) has the potential to protect against all peanut allergens. The mouse anaphylaxis model of peanut allergy demonstrated that the vaccine candidate exhibited a non-reactogenic profile after intravenous challenge with whole peanut extract. This result further supports the hypo-allergic potential of VLP Peanut, in alignment with the results previously demonstrated using human blood cells, which is a vital quality in delivering a viable peanut allergy vaccine. Additional data being presented show that a single dose of VLP Peanut protected mice against anaphylaxis in a peanut sensitized mouse model. The upcoming Phase I PROTECT trial, the first human study exploring the potential of this peanut vaccine candidate will begin later in 2022, following FDA clearance of the Group's IND application, with topline data expected in 2023. The posters will be presented at the WAO & BSACI UK Conference on Tuesday 26 April between 11:05 - 14:00 (BST) https://wao-bsaci.org/ . Abstracts of each will be made available on the Company website.
13/4/2022
11:46
jimmyloser: My take is that it is too soon, AGY have had several setbacks. Suitors will surely wish to see the outcome of 'in human' peanut trials rather than laboratory. IF, they can deliver this time, impo, they do have the fundamentals of a bidding war and a pay day! Very risky still, but risk equals reward.
13/4/2022
11:33
jpuff: The Glaxo bid for Sierra might hopefully spark interest in smaller cap pharma stocks. SAR has reacted positively but alas not AGY yet. Different field of treatment but nonetheless attractive to a suitor imo
07/3/2022
08:00
jimmyloser: RNS Non-Regulatory TIDMAGY Allergy Therapeutics PLC 07 March 2022 Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group") Allergy Therapeutics to present on Investor Meet Company platform 7 March 2022 Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces that Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief Financial Officer, and Alan Bullimore, Head of Business Innovation, will be providing a live presentation relating to the Group's recently announced Interim Results for the six months ended 31 December 2021 on the Investor Meet Company platform, on Thursday 10 March 2022 at 10:30am GMT. The presentation is open to all existing and potential shareholders and will be followed by a Q&A session. Questions can be submitted ahead of the event through the Investor Meet Company dashboard until 9am GMT on Wednesday 9 March, or at any time during the live presentation. To sign up to Investor Meet Company for free, and to register for the Group's presentation, please visit: https://www.investormeetcompany.com/allergy-therapeutics-plc/register-investor . Those already following All
03/3/2022
07:03
wizzkid211: Allergy Therapeutics PLC Allergy Therapeutics plc -- Interim Results 03/03/2022 7:01am UK Regulatory (RNS & others) Allergy Therapeutics (LSE:AGY) Intraday Stock Chart Thursday 3 March 2022 Click Here for more Allergy Therapeutics Charts. TIDMAGY RNS Number : 5111D Allergy Therapeutics PLC 03 March 2022 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company" or the "Group") Interim Results for the six months ended 31 December 2021 US readiness plan underway including two pivotal trials -- Portfolio focused on high value growth products to enhance future profitability -- Ground-breaking Phase I trial of peanut allergy vaccine on track to commence in 2022 following recent FDA clearance of IND application with data expected sooner than previously anticipated -- Pivotal Phase III trial of short-course grass pollen immunotherapy to commence in Q3 2022 following impressive results from exploratory field trial -- Solid revenue of GBP49m, increased cash position of GBP41m 3 March 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces its unaudited interim results for the six months ended 31 December 2021. Highlights Financial -- Solid revenue from commercial portfolio of GBP48.7m. Strategic streamlining of older products has affected a short-term revenue decrease of 10% (5% at constant currency* and up 4% on like for like constant currency* plus phasing) from GBP54.0m in H1 2021 -- Operating profit pre-R&D of GBP12.5m (H1 2021 GBP20.5m) reflecting portfolio streamlining and activity to pre-Covid-19 levels -- Increased cash balance of GBP41.4m (30 June 2021: GBP40.3m). Net cash of GBP38.5m (30 June 2021 GBP36.9m) -- GBP10m revolving credit facility signed post period to replace previous GBP7m overdraft facility -- Strong outlook for the full year with operating profit (pre-R&D) expected to be in line with consensus forecasts Operational -- IND application cleared by the United States Food & Drug Administration (FDA) for peanut allergy vaccine candidate, VLP Peanut, with initial patient treatment due to begin in 2022 and top line data expected H1 2023, earlier than originally intended data readout of Q4 2023 o $8bn per annum market opportunity o VLP Peanut has the potential to provide long-term immune response in comparison to continual dosing required by other treatments -- Impressive results from exploratory field trial of wholly owned short-course grass pollen immunotherapy, Grass MATA MPL, enabling pivotal Phase III trial to begin in Q3 2022 -- Growth of key commercial portfolio products, Pollinex, Venomil and Acarovac Manuel Llobet, CEO at Allergy Therapeutics , stated: "This year will see the Company prepare for entry into the US market where the allergy immunotherapy market is estimated to be worth $2 billion . Our Company continues to stand out as a high value hybrid, with its strong commercial business and high science R&D programmes. We are well placed to create shareholder value through our pivotal stage grass pollen immunotherapy and our innovative peanut allergy vaccine, both of which have significant potential in the US market. "Our strong cash position and commercial capabilities give Allergy Therapeutics a highly differentiated position and opportunity to investors compared to solely R&D-focused healthcare companies." *Constant currency uses prior year weighted average exchange rates to translate current year foreign currency denominated revenue to give a year-on-year comparison excluding the effects of foreign exchange movements. See table in finance review for an analysis of revenue. This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014. -S - Analyst briefing and webcast today Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief Financial Officer, and Alan Bullimore, Head of Business Innovation, will host a virtual presentation for analysts to provide an update on the Group, followed by a Q&A session, at 09.30am GMT. The live webcast can be accessed here . For further information, please contact: Allergy Therapeutics +44 (0) 1903 845 820 Manuel Llobet, Chief Executive Officer Nick Wykeman, Chief Financial Officer Panmure Gordon
01/3/2022
08:37
jimmyloser: 01 March 2022 Al l er gy Therapeu tics p lc (" A l l ergy Ther apeut ics", the "Group" or "C o mpany ") Allergy Therapeutics shares positive new data at the 2022 American Academy of Allergy Asthma and Immunology Annual Meeting - Five posters presented including highly successful results from Grass MATA MPL G309 exploratory field trial and ex-vivo VLP001 biomarker study examining potential of VLP Peanut - Data show clinically meaningful and statistically significant reductions in symptoms due to grass pollen allergy and in the use of relief medications after six SCIT injections with Grass MATA MPL during peak grass pollen season - Convincing data presented from VLP001 ex-vivo biomarker study show VLP Peanut has potential to modulate T cell, B cell and dendritic cell responses, promoting the protective tolerogenic pathway and highlighting the potential as an effective treatment for peanut allergy 1 March 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces the presentation of positive new data from its two lead immunotherapy programmes at the 2022 American Academy of Allergy Asthma and Immunology Annual Meeting held in Phoenix, Arizona. Allergy Therapeutics presented extensive results from the G309 exploratory field trial demonstrating efficacy and safety of Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate, that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. This was a multi-centre, double-blind, placebo-controlled, randomised and parallel-group clinical trial with subjects enrolled across 13 sites in Germany and the US. -- The presentations revealed a more pronounced, clinically relevant and statistically significant improvement in the primary combined symptom and medication score compared to the historically used placebo group (used for Phase II and planned for the upcoming pivotal Phase III study G306) - a 33.1% (p=0.0325) and 39.5% (p=0.0112) effect size on the primary endpoint for the conventional and extended posology groups, respectively. -- This 39.5% improvement is higher than the 36.8% figure initially reported by the Group in October 2021 where the two placebo groups were combined. These results further highlight the superior treatment effect sizes achieved after six injections of Grass MATA MPL. -- The Group also presented post-hoc analyses of an earlier Phase II grass trial highlighting the strong predictive value of the baseline CPT (conjunctival provocation test) score for IgG4 increase after SCIT treatment, providing a rationale for the design of the upcoming pivotal G306 Phase III trial due to commence in the autumn of this year. -- The Company also provided details of a pollen monitoring network established by Allergy Therapeutics in the US, with central reading procedures to accurately measure daily pollen counts and better establish the peak grass pollen season - an important requirement for determining the primary study results of the G306 Phase III trial. Dr Mohamed Shamji, Reader in Immunology & Allergy, Imperial College London, presented data from the VLP001 ex-vivo biomarker study investigating the Group's peanut allergy vaccine candidate, VLP Peanut. The data presented showed that VLP Peanut does not elicit an allergic reaction (i.e. it is hypoallergenic) and results in a significant reduction in basophil activation and histamine release from peanut allergic subjects, when compared to the major allergen, Ara h2, and whole peanut extract. These biomarker results provide strong confidence in the potential beneficial immunologic mode of action of VLP Peanut in promoting class switching from the allergic Th2 pathway to the more tolerogenic Th1 pathway, underlining VLP Peanut's potential as an effective treatment for peanut allergy. Manuel Llobet, Chief Executive Officer, commented: "Demonstrating a nearly 40% reduction in combined symptom and medication score compared to placebo in a grass pollen allergy trial is a significant event in our history. We are very much looking forward to the pivotal G306 clinical trial of our Grass MATA MPL immunotherapy that is due to commence later this year and, if successful, would enable registration in Europe and the US. Such a product would permit patients suffering from grass pollen allergy the opportunity to address the cause of their disease, not just mask their symptoms. I am also very proud to see the data from our VLP001 study being presented internationally - data that provides us with confidence in the product profile of our novel short course peanut allergy vaccine candidate as we head into the clinic later this year."
13/1/2022
08:00
wizzkid211: Allergy Therapeutics PLC Half Year Trading Update & Notice of Results 13/01/2022 7:00am UK Regulatory (RNS & others) Allergy Therapeutics (LSE:AGY) Intraday Stock Chart Thursday 13 January 2022 Click Here for more Allergy Therapeutics Charts. TIDMAGY RNS Number : 2762Y Allergy Therapeutics PLC 13 January 2022 Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group") Half Year Trading Update 2022 and Notice of Results - VLP Peanut IND application submitted to FDA with a protocol enabling Phase I trial (named PROTECT); expected results in H1 2023 ahead of original Q4 2023 data readout - IMP VLP Peanut batch manufactured and ready for start of upcoming PROTECT trial - Strategic streamlining of products to focus on SCIT and innovative allergy treatments - Strong cash position to support Grass MATA MPL pivotal Phase III field studies and Phase I VLP Peanut PROTECT trial - Phase III Grass MATA MPL trial on track to start Q3 2022 following impressive results from exploratory field trial 13 January 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provides a trading update for the six months ended 31 December 2021 ahead of its Half Year Results to be announced on 3 March 2022. Financials Reported revenues for the six months ended 31 December 2021 are expected to be GBP48.7m (2020: GBP54.0m), representing a 10% reduction on a reported basis (down 5% on constant currency basis). This is primarily due to the previously disclosed strategic streamlining of non-differentiated older products to maintain focus on short course subcutaneous immunotherapy (SCIT) and innovative allergy treatments. On this revised basis revenues have increased 3% on a like for like product and phasing basis (on constant currency basis). Revenues were also affected by phasing, headwinds in Germany and the continuing effect of COVID-19 in Italy and Germany. However Spain, the Group's second most important market, saw a double-digit growth in sales, while the Netherlands, UK and Rest of World (RoW) also grew strongly. There was double-digit growth for key products Pollinex, Venomil and Acarovac (on constant currency basis). Reported revenue for the year is likely to be down on the 2021 financial year by an upper single digit percentage, but through planned cost reductions in the second half of the year, the Board remains confident that market consensus for the operating profit pre R&D this financial year will be achieved. The Group has continued to generate good cash conversion, with a strong cash balance at the end of December 2021 of GBP41.4m (31 December 2020: GBP48.3m). On current internal assumptions and as previously communicated, the Group will be able to fund the Grass MATA MPL Phase III trial (G306), as well as the VLP Peanut Phase I PROTECT trial, from existing resources with a small amount of additional debt. Regulatory The Group has successfully submitted the Investigational New Drug (IND) application for VLP Peanut to the US Food and Drug Administration (FDA). Following consultation with experts in the field, the IND application includes a protocol for the upcoming Phase I PROTECT trial, moving the planned paediatric and adolescent arms into a future Phase II trial. As a result, topline data from the Phase I PROTECT trial, in adult patients, would be anticipated in H1 2023, ahead of the original intended Q4 2023 data readout. Furthermore, the batch of investigational medicinal product (IMP) intended for use in the upcoming Phase I PROTECT trial has been successfully manufactured, tested and released. This product aims to revolutionise the peanut allergy market as a treatment that has the potential to provoke a disease-modifying effect and to bring a significant positive impact to the lives of patients and families affected by peanut allergy, and to health systems. The market for peanut allergies is expected to be around $8bn worldwide. Following the outcome of the Grass MATA MPL exploratory field trial in October 2021 which showed efficacy of 36.8% in an extended posology, the Group is now on track to begin the Grass MATA MPL pivotal Phase III trial (G306) in the autumn of this calendar year. Manuel Llobet, CEO at Allergy Therapeutics , stated: "2022 is going to be a pivotal year for Allergy Therapeutics with the VLP Peanut Phase I PROTECT trial and MATA MPL Phase III trial (G306) commencing during the calender year. We continue to be very encouraged by the data and the clinical progress supporting these highly innovative product trials. The Group has continued to perform and I am encouraged by our response to the challenges from what continues to be a tough environment. Our focus on providing innovative allergy treatments to patients in need, as well as delivering a strong, differentiated R&D pipeline remains key to our strategy. We are confident in the Group's commercial capabilities despite being cautious due to COVID-related uncertainties and we look forward to reporting the significant progress expected in our clinical pipeline." This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.
12/11/2021
13:59
km18: AGY is a visionary immunology business focused on R&D of allergy treatments and operating in Europe and looking forward to US market opportunity. The company specializes in diagnosis and treatment of allergy. What differentiates them is that average treatment in the market is of around 12-15 course injections, whereas theirs consists of 6. They have growing market share in EU and aim to enter the largest allergy market – the US, further supported by 8 new products in their pipeline. AGY has generated a 25% pre-R&D increase in operating profit in 2020. Operating performance in 2016 was affected by big expenditures on R&D. 2020 gross performance has supported successfully the R&D investments in the group. The company has seen significant increase in cash with low movements in accruals. Cash is expected to further increase, and operating profit is expected to be 8% above expectations. Latest report consisting the preliminary annual results are definitely in favour of the stock. Revenue grew by 8% reaching the Stockopedia forecasted figure of £84.3m. Net profit is above the forecast at £2.9m and gross profit is ahead of 2020 figures. We should note that profit for the year is significantly below the last year’s level due to high R&D cost (more than double the 2020). Outlook is positive and they have new trials coming...keep up to date with stocks with WealthOracleAM https://wealthoracle.co.uk/detailed-result-full/AGY/162
Allergy Therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
AGY
Allergy Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220702 02:23:24